DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Andtbacka RH, Collichio F, Harrington KJ. et al.
Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.
J Immunother Cancer 2019;
7: 145
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.